Literature DB >> 1686743

Dopaminergic brain reward regions of Lewis and Fischer rats display different levels of tyrosine hydroxylase and other morphine- and cocaine-regulated phosphoproteins.

D Beitner-Johnson1, X Guitart, E J Nestler.   

Abstract

We studied cyclic AMP-dependent protein phosphorylation in the mesolimbic and nigrostriatal dopamine systems of two genetically inbred rat strains, Lewis (LEW) and Fischer (F344) rats. These strains represent genetically divergent populations of rats that have been used to study possible genetic factors involved in a variety of biological processes. We found striking differences in levels of tyrosine hydroxylase, and several other phosphoproteins, in the mesolimbic, but not the nigrostriatal, dopamine system between the two rat strains. Interestingly, in Sprague-Dawley rats, these same phosphoproteins are altered by chronic morphine and chronic cocaine specifically in the mesolimbic dopamine system, generally thought to be a brain reward pathway that mediates some of the reinforcing actions of many drugs of abuse. As LEW and F344 rats have been reported to show different levels of preference for several types of drugs of abuse, the results are consistent with the possibility that these phosphoproteins may mediate aspects of drug reinforcement and contribute to individual differences in vulnerability to drug addiction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686743     DOI: 10.1016/0006-8993(91)90759-o

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Delay discounting in Lewis and Fischer 344 rats: steady-state and rapid-determination adjusting-amount procedures.

Authors:  Jeffrey S Stein; Jonathan W Pinkston; Adam T Brewer; Monica T Francisco; Gregory J Madden
Journal:  J Exp Anal Behav       Date:  2012-05       Impact factor: 2.468

2.  Animal models of gene-environment interactions in schizophrenia.

Authors:  Yavuz Ayhan; Akira Sawa; Christopher A Ross; Mikhail V Pletnikov
Journal:  Behav Brain Res       Date:  2009-04-18       Impact factor: 3.332

Review 3.  Running is rewarding and antidepressive.

Authors:  Stefan Brené; Astrid Bjørnebekk; Elin Aberg; Aleksander A Mathé; Lars Olson; Martin Werme
Journal:  Physiol Behav       Date:  2007-05-21

Review 4.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

5.  Amphetamine self-administration and dopamine function: assessment of gene × environment interactions in Lewis and Fischer 344 rats.

Authors:  Andrew C Meyer; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2015-01-09       Impact factor: 4.530

6.  3,4-Methylenedioxypyrovalerone (MDPV)-induced conditioned taste avoidance in the F344/N and LEW rat strains.

Authors:  Heather E King; Bradley Wetzell; Kenner C Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2014-10-02       Impact factor: 3.533

7.  Differences in response to an acoustic startle stimulus among forty-six rat strains.

Authors:  J R Glowa; C T Hansen
Journal:  Behav Genet       Date:  1994-01       Impact factor: 2.805

8.  Compared with DBA/2J mice, C57BL/6J mice demonstrate greater preference for saccharin and less avoidance of a cocaine-paired saccharin cue.

Authors:  Christopher S Freet; Amanda Arndt; Patricia S Grigson
Journal:  Behav Neurosci       Date:  2013-04-01       Impact factor: 1.912

9.  Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration.

Authors:  Marta Valenza; Roberto Picetti; Vadim Yuferov; Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Neuropharmacology       Date:  2016-01-09       Impact factor: 5.250

10.  Differences in performance between Sprague-Dawley and Fischer 344 rats in positive reinforcement tasks.

Authors:  Jesse S Rodriguez; Sherin Y Boctor; Clyde F Phelix; Joe L Martinez
Journal:  Pharmacol Biochem Behav       Date:  2007-11-06       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.